News
News
Current position:News > News
News
The Multifaceted Role of Claudin-1: Regulation of Cancer, Inflammation, and Fibrosis with Therapeutic Implications
Claudin-1 (CLDN1) is emerging as a game-changing target in disease therapy, attracting global attention for its potential to transform the treatment of liver diseases, cancer, and beyond. With innovative therapies already advancing in the clinic, CLDN1 is at the forefront of a new era in precision medicine.
2025-09-10
OX40L:Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study
2025-09-05
TSLP: The Emerging Key Target in Autoimmune Diseases
2025-09-05
Rise of PD-1/VEGF/CTLA-4 Triple Antibodies: Immunotherapy 2.0 and Its Accelerated Development
2025-09-05
DLL3 Target Trend Surges: A Rising Star in Small Cell Lung Cancer Therapy
DLL3 is quickly becoming one of the most exciting targets in small cell lung cancer. After early challenges, new approaches are showing strong results in clinical trials. With high tumor specificity, promising safety, and billion-dollar partnerships shaping the field, DLL3 therapies are on track to transform treatment options while creating major opportunities in oncology drug development.
2025-09-03
GLP-1R/GCGR/GIPR:Novo Nordisk Delivers Strong H1 2025 Results, Driven by Soaring GLP-1 Drug Sales
2025-08-07
Securing Market Share in the IL-17 Era: First Movers vs Fast Followers
As IL-17 continues to solidify its role in immunology and autoimmune disease treatment, the therapeutic landscape is evolving rapidly. From the intricacies of cytokine signaling to market dynamics shaped by innovation, pricing, and strategic positioning, understanding the competitive landscape is essential.
2025-08-01
GLP1R:Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
2025-07-31
OX40/OX40L: Broadly Involved in Inflammation, Autoimmunity, and Cancer
OX40 is gaining momentum as a high-value target in next-generation immunomodulation.

With its pivotal role in T cell co-stimulation and involvement in both oncology and autoimmune diseases, OX40 has attracted increasing clinical attention. Multiple assets targeting this pathway are advancing through late-stage trials, marking a new wave of immune-focused therapeutic strategies.
2025-07-24
CLDN18.2×4-1BB:I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
2025-07-18
First 1 2 3 4 5 Last
Total 5 Page
Jump
Current position:News > News
classify
News
The Multifaceted Role of Claudin-1: Regulation of Cancer, Inflammation, and Fibrosis with Therapeutic Implications
Claudin-1 (CLDN1) is emerging as a game-changing target in disease therapy, attracting global attention for its potential to transform the treatment of liver diseases, cancer, and beyond. With innovative therapies already advancing in the clinic, CLDN1 is at the forefront of a new era in precision medicine.
2025-09-10
OX40L:Sanofi’s amlitelimab met all primary and key secondary endpoints in the COAST 1 phase 3 study
2025-09-05
TSLP: The Emerging Key Target in Autoimmune Diseases
2025-09-05
Rise of PD-1/VEGF/CTLA-4 Triple Antibodies: Immunotherapy 2.0 and Its Accelerated Development
2025-09-05
DLL3 Target Trend Surges: A Rising Star in Small Cell Lung Cancer Therapy
DLL3 is quickly becoming one of the most exciting targets in small cell lung cancer. After early challenges, new approaches are showing strong results in clinical trials. With high tumor specificity, promising safety, and billion-dollar partnerships shaping the field, DLL3 therapies are on track to transform treatment options while creating major opportunities in oncology drug development.
2025-09-03
GLP-1R/GCGR/GIPR:Novo Nordisk Delivers Strong H1 2025 Results, Driven by Soaring GLP-1 Drug Sales
2025-08-07
Securing Market Share in the IL-17 Era: First Movers vs Fast Followers
As IL-17 continues to solidify its role in immunology and autoimmune disease treatment, the therapeutic landscape is evolving rapidly. From the intricacies of cytokine signaling to market dynamics shaped by innovation, pricing, and strategic positioning, understanding the competitive landscape is essential.
2025-08-01
GLP1R:Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited
2025-07-31
OX40/OX40L: Broadly Involved in Inflammation, Autoimmunity, and Cancer
OX40 is gaining momentum as a high-value target in next-generation immunomodulation.

With its pivotal role in T cell co-stimulation and involvement in both oncology and autoimmune diseases, OX40 has attracted increasing clinical attention. Multiple assets targeting this pathway are advancing through late-stage trials, marking a new wave of immune-focused therapeutic strategies.
2025-07-24
CLDN18.2×4-1BB:I-Mab Strengthens Givastomig Intellectual Property Portfolio through Acquisition of Bridge Health
2025-07-18
MORE
Message consultation
reset
submit
Service
Message
Message consultation
reset
submit